1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Anal Fistula Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Anal Fistula Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Anal Fistula Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2017–2031
6.3.1. Non-surgical
6.3.1.1. Drugs
6.3.1.2. Others (fibrin glue, adipose stem cell therapy, etc.)
6.3.2. Surgical
6.3.2.1. Fistulotomy
6.3.2.2. Bioprosthetic Plus
6.3.2.3. Advancement Flap Procedures
6.3.2.4. Seton Techniques
6.3.2.5. Others
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Anal Fistula Treatment Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Intersphincteric
7.3.2. Transsphincteric
7.3.3. Suprasphincteric
7.3.4. Extrasphincteric
7.3.5. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Anal Fistula Treatment Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals & Ambulatory Surgical Centers
8.3.2. Clinics
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Anal Fistula Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Anal Fistula Treatment Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Treatment Type, 2017–2031
10.3.1. Non-surgical
10.3.1.1. Drugs
10.3.1.2. Others (fibrin glue, adipose stem cell therapy, etc.)
10.3.2. Surgical
10.3.2.1. Fistulotomy
10.3.2.2. Bioprosthetic Plus
10.3.2.3. Advancement Flap Procedures
10.3.2.4. Seton Techniques
10.3.2.5. Others
10.4. Market Value Forecast, by Application, 2017–2031
10.4.1. Intersphincteric
10.4.2. Transsphincteric
10.4.3. Suprasphincteric
10.4.4. Extrasphincteric
10.4.5. Others
10.5. Market Value Forecast, by End-user, 2017–2031
10.5.1. Hospitals & Ambulatory Surgical Centers
10.5.2. Clinics
10.5.3. Others
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Treatment Type
10.7.2. By Application
10.7.3. By End-user
10.7.4. By Country
11. Europe Anal Fistula Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Treatment Type, 2017–2031
11.3.1. Non-surgical
11.3.1.1. Drugs
11.3.1.2. Others (fibrin glue, adipose stem cell therapy, etc.)
11.3.2. Surgical
11.3.2.1. Fistulotomy
11.3.2.2. Bioprosthetic Plus
11.3.2.3. Advancement Flap Procedures
11.3.2.4. Seton Techniques
11.3.2.5. Others
11.4. Market Value Forecast, by Application, 2017–2031
11.4.1. Intersphincteric
11.4.2. Transsphincteric
11.4.3. Suprasphincteric
11.4.4. Extrasphincteric
11.4.5. Others
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals & Ambulatory Surgical Centers
11.5.2. Clinics
11.5.3. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Treatment Type
11.7.2. By Application
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Anal Fistula Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Treatment Type, 2017–2031
12.3.1. Non-surgical
12.3.1.1. Drugs
12.3.1.2. Others (fibrin glue, adipose stem cell therapy, etc.)
12.3.2. Surgical
12.3.2.1. Fistulotomy
12.3.2.2. Bioprosthetic Plus
12.3.2.3. Advancement Flap Procedures
12.3.2.4. Seton Techniques
12.3.2.5. Others
12.4. Market Value Forecast, by Application, 2017–2031
12.4.1. Intersphincteric
12.4.2. Transsphincteric
12.4.3. Suprasphincteric
12.4.4. Extrasphincteric
12.4.5. Others
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals & Ambulatory Surgical Centers
12.5.2. Clinics
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Treatment Type
12.7.2. By Application
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Anal Fistula Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Treatment Type, 2017–2031
13.3.1. Non-surgical
13.3.1.1. Drugs
13.3.1.2. Others (fibrin glue, adipose stem cell therapy, etc.)
13.3.2. Surgical
13.3.2.1. Fistulotomy
13.3.2.2. Bioprosthetic Plus
13.3.2.3. Advancement Flap Procedures
13.3.2.4. Seton Techniques
13.3.2.5. Others
13.4. Market Value Forecast, by Application, 2017–2031
13.4.1. Intersphincteric
13.4.2. Transsphincteric
13.4.3. Suprasphincteric
13.4.4. Extrasphincteric
13.4.5. Others
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals & Ambulatory Surgical Centers
13.5.2. Clinics
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Treatment Type
13.7.2. By Application
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Anal Fistula Treatment Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Treatment Type, 2017–2031
14.3.1. Non-surgical
14.3.1.1. Drugs
14.3.1.2. Others (fibrin glue, adipose stem cell therapy, etc.)
14.3.2. Surgical
14.3.2.1. Fistulotomy
14.3.2.2. Bioprosthetic Plus
14.3.2.3. Advancement Flap Procedures
14.3.2.4. Seton Techniques
14.3.2.5. Others
14.4. Market Value Forecast, by Application, 2017–2031
14.4.1. Intersphincteric
14.4.2. Transsphincteric
14.4.3. Suprasphincteric
14.4.4. Extrasphincteric
14.4.5. Others
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals & Ambulatory Surgical Centers
14.5.2. Clinics
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Treatment Type
14.7.2. By Application
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Becton, Dickinson and Company
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Biolitec AG
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Cook Medical
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Gem srl
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. KARL STORZ SE & Co. KG
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Medtronic plc
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. TiGenix NV
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. W.L. Gore & Associates, Inc. (Gore Medical)
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/